Graham McClelland is a Professor of Pharmaceutical Medicine in the Medicines Development Group within the Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences.

Professor McClelland spent over 30 years working in R&D for the pharmaceutical industry with Beecham (now part of GlaxoSmithKline) and Roche, holding senior international leadership positions in clinical research. He is a qualified biologist, psychologist and pharmacologist, and obtained his PhD in clinical psychopharmacology from Hatfield Polytechnic by part-time study. In 1999 he initiated a part-time MSc course in Clinical Pharmacology at the Postgraduate Medical School of the University of Surrey, where he was a Visiting Professor and the Course Director until 2009. In 2009 he left his position of Head of UK Clinical Research at Roche, to move to Egypt, where he formed the public company, Luxor Developments, and carried out teaching and consultancy work in the region. He was appointed a Visiting Professor in the Faculty of Medicine of the University of Alexandria in 2011. He returned to the UK in 2015, and shortly after, was appointed as a Non-Executive Director and, subsequently, Chair of the Clinical and Quality Assurance Committee, of Quantum Care, a leading UK not-for-profit organisation that provides residential care for the elderly.

Professor McClelland has published over 60 book chapters and research articles, holds three patents, and has spoken and chaired conferences across the globe. He has served as a member of several advisory bodies including for the ABPI, the Department of Health, the charity Ataxia UK, and as an adviser to businesses including the independent sustainability consultancy company, Article 13. In 2018 he joined King’s as a Visiting Professor, where teaches on the pharmaceutical medicine MSc courses.

He currently has broad research interests in the development of new medicines, patient engagement and corporate social responsibility in the pharmaceutical industry.